This treatment option often costs several hundred dollars per month without insurance coverage
Ozempic is a GLP-1 receptor agonist licensed for type 2 diabetes treatment, administered as a once-weekly subcutaneous injection
Our study also found that, in general, patients without type 2 diabetes experienced greater weight loss than patients with type 2 diabetes, but tirzepatide was more effective than semaglutide in both groups. Study author Nick Stucky, MD, PhD, vice president of Truveta Research and practicing infectious disease physician with Providence Portland Medical Center, noted the following about the study to Medical News Today: While tirzepatide was significantly more effective than semaglutide, patients on both medications experienced substantial weight loss and we observed no difference in the risk of GI adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate
Russo MF, Lembo E, Mari A et al (2021) Insulin resistance is central to long-term reversal of histologic nonalcoholic steatohepatitis after metabolic surgery
Understanding how Ozempic typically functions helps patients recognise what to expect and identify when their experience differs from the norm, which may warrant discussion with their healthcare provider
